BioCryst Pharmaceuticals BCRX ORLADEYO — Total trade receivables

Similar metrics at other companies

CHDNTrade receivables — Accounts receivable

$58M+18.1%

NGSRentals — Trade accounts receivable

$19.87M+58.6%

HNSTTrade Agreements — Trade agreements asset

$100K—

CSVCemetery — Trade and financed receivables

$33.66M+28.0%

NGSSales and aftermarket services — Trade accounts receivable

$2.55M+46.9%

NTRSTrust Fees Receivable, net — Total Client Receivables

$1.01B+4.0%

FAQ

What is BioCryst Pharmaceuticals's ORLADEYO — total trade receivables?

BioCryst Pharmaceuticals (BCRX) reported ORLADEYO — total trade receivables of $104.46M in Q2 2026.

How has BioCryst Pharmaceuticals's ORLADEYO — total trade receivables changed year-over-year?

BioCryst Pharmaceuticals's ORLADEYO — total trade receivables increased by 19.3% year-over-year, from $87.58M to $104.46M.

What is the long-term trend for BioCryst Pharmaceuticals's ORLADEYO — total trade receivables?

Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's ORLADEYO — total trade receivables has grown at a 45.0% compound annual growth rate (CAGR), from $81.08M to $358.45M.

What does ORLADEYO — total trade receivables mean?

This metric represents the outstanding balance of payments owed by customers for products delivered within this specific segment. Monitoring this helps assess the credit quality of the customer base and the efficiency of the company's cash collection cycle.